SYS-CON MEDIA Authors: Jason Bloomberg, Eric Brown, Bob Gourley, Sandi Mappic, RealWire News Distribution

News Feed Item

Mid-Atlantic Lays Claim to Majority of Pharma-Biotech's $3.5 Billion Investment in Construction Starts in First-Quarter 2014, an Industrial Info News Alert

SUGAR LAND, TX -- (Marketwired) -- 02/11/14 -- Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Virtually every region of North America is home to some form of construction activity sourced out of the Pharmaceutical-Biotech Industry, with plans to kick off $3.5 billion in the form of 165 projects in the first three months of the year. Laying claim to the biggest slice of that lucrative pie is the Mid-Atlantic region, with $783 million divided among 19 projects on the books for a first-quarter 2014 kickoff.

Other companies featured: Colgate-Palmolive (NYSE:CL), AstraZeneca (NYSE:AZN), Bristol-Myers Squibb (NYSE:BMY)

For details, view the entire article by subscribing to Industrial Info's Premium Industry News at http://www.industrialinfo.com/news/abstract.jsp?newsitemID=240644&refer=mw, or browse other breaking industrial news stories at www.industrialinfo.com.

Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, three offices in North America and nine international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle¬ô, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. To contact an office in your area, visit the www.industrialinfo.com "Contact Us" page.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Joe Govreau
713-783-5147

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.